Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257
T0 and dynamic changes of cfDNA, TF and VAF may help physicians to stratify ES-SCLC patients receiving first-line ACE and to anticipate the clinical course of the disease.
Authors
- Stefano Indraccolo (ORCID: https://orcid.org/0000-0002-4810-7136)
- Valentina Guarneri (ORCID: https://orcid.org/0000-0002-2375-8397)
- Elisabetta Lazzarini (ORCID: https://orcid.org/0000-0002-7284-999X)
- Daniela Scattolin (ORCID: https://orcid.org/0000-0003-2619-5945)
- Maria Vittoria Resi
- Alessandra Ferro (ORCID: https://orcid.org/0000-0002-1163-3765)
- Anna Roma
- Alessandro Dal Maso (ORCID: https://orcid.org/0000-0003-3743-717X)
- Giorgio Pigato
- Chiara Romualdi (ORCID: https://orcid.org/0000-0003-4792-9047)
- Giulia Pasello (ORCID: https://orcid.org/0000-0002-8741-6038)
- Sara Potente
- Laura Bonanno
- Stefano Frega
- Stefania Lando (ORCID: https://orcid.org/0009-0006-2622-0628)
Institutions
- University of Padua (IT)
- Istituto Oncologico Veneto (IT)
- Ospedale San Bortolo (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1186/s13046-025-03434-3
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Università degli Studi di Padova
- Istituto Oncologico Veneto